Investigating the Cellular Impact of 8-oxo-Guanine on DNA Replication and Genome Stability
Project Number4R00ES033771-03
Former Number5K99ES033771-02
Contact PI/Project LeaderBARNES, RYAN P
Awardee OrganizationUNIVERSITY OF KANSAS MEDICAL CENTER
Description
Abstract Text
PROJECT SUMMARY (See instructions):
Excess reactive oxygen species, or oxidative stress, is a ubiquitous condition humans experience that damages
the entire cell. Importantly, oxidative stress damages DNA resulting in numerous lesions that can halt DNA
replication and increase mutagenesis. Oxidative stress emanates from various endogenous sources (metabolism,
inflammation, etc.) but also exogenous environmental sources such as pollution, smoking, and ultraviolet radiation
(UVR), arguably the most universal source of oxidative stress and DNA damage humans encounter. 8-oxodeoxyguaine
(8oxoG) is a principle adduct generated by oxidative stress, and while well studied in vitro, is
historically difficult to investigate in cells since the agents used to produce it (UVA, hydrogen peroxide, etc.) also
generate other DNA lesions, and damage lipids and proteins in the cell. Our group developed and published on a
novel fluorogen activated peptide (FAP) which can bind malachite green photosensitizer dyes and when excited
with far-red light, specifically produces singlet oxygen. Singlet oxygen is known to have a short half-life and reacts
rapidly with guanine to form 8oxoG. By fusing FAP to the telomere binding protein TRF1, we demonstrated the
specificity of our chemoptogenetic system, and its spatial and temporal control. We also generated cells which
express FAP fused to the histone H2B (H2B-FAP), allowing for genome-wide production of 8oxoG. The overall
hypothesis of this proposal is that 8oxoG stalls DNA replication forks, especially at repetitive DNA sequences like
telomeres, requiring the activities of ATR, Pol IJ, and PrimPol. This proposal is uniquely poised to address this
hypothesis, as the H2B-FAP and TRF1-FAP tools are the only methods available to specifically induce 8oxoG
within the human genome. In addition to telomeres, use of H2B-FAP will allow for the identification of other
sequences sensitive to 8oxoG formation by examining the binding of replication stress response factors. Using
physiological conditions, these identified sequences as well as telomere repeats will be studied in vitro to
determine if they stall replicative DNA polymerases. This combination of biochemical and cellular replication
studies will fill a critical gap in our knowledge of how 8oxoG impacts replication fork integrity and cell
fate. Oxidative stress is linked to various diseases including cancer, but also aging. However, due to its pleiotropic
effects, it is difficult to attribute any specific outcome to a particular lesion. While this study will advance our general
understanding of 8oxoG, it will directly compare H2B-FAP activation with UVR, which induces pyrimidine dimers
in addition to oxidative stress. UVR promotes skin carcinogenesis especially in the absence of factors like Pol 11,
the protein mutated in the cancer predisposition syndrome, XPV. This study will examine the direct role of Pol 11
and other DNA replication factors (ATR, PrimPol, FANCD2, and MacroH2A1 .2) in the cellular response to 8oxoG.
National Institute of Environmental Health Sciences
CFDA Code
113
DUNS Number
016060860
UEI
YXJGGNC5J269
Project Start Date
01-November-2023
Project End Date
31-October-2026
Budget Start Date
01-November-2023
Budget End Date
31-October-2024
Project Funding Information for 2024
Total Funding
$249,000
Direct Costs
$165,436
Indirect Costs
$83,564
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Environmental Health Sciences
$249,000
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 4R00ES033771-03
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 4R00ES033771-03
Patents
No Patents information available for 4R00ES033771-03
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 4R00ES033771-03
Clinical Studies
No Clinical Studies information available for 4R00ES033771-03
News and More
Related News Releases
No news release information available for 4R00ES033771-03
History
No Historical information available for 4R00ES033771-03
Similar Projects
No Similar Projects information available for 4R00ES033771-03